Business Wire

VA-REGULA

16.11.2023 09:01:35 CET | Business Wire | Press release

Share
Regula Survey Reveals Countries Less Equipped for Digital Nomads

When investigating digital nomads' journey as new clients, Regula compiled a list of the ten most common activities in various locations spanning the United States, United Kingdom, Germany, Spain, United Arab Emirates, and Mexico. They then called upon respondents to pinpoint the activities causing the utmost distress. Through this approach, the survey brought to light a comparative ranking of countries where businesses encounter difficulties in accommodating users who possess foreign identity documents.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231116009610/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Regula conducted a survey in which they identified the ten most common activities for digital nomads in various locations, encompassing the United States, United Kingdom, Germany, Spain, United Arab Emirates, and Mexico. They asked respondents to highlight the activities causing the utmost distress. This revealed a list of countries where businesses struggle to accommodate users with foreign passports. (Graphic: Business Wire)

Interestingly, nomads are expressing the most frustration when interacting with organizations offering services in the United States. This revelation comes as a surprise, given that the United States was the most frequented destination for the digital nomad community in 2022.

The most painful verification processes for nomads in the USA are linked to specific stages: crossing the border (21 percent of respondents), checking into a hotel (19 percent), renting accommodations (19 percent), activating a new mobile phone or SIM card (17 percent), and securing a rental car (14 percent).

In the second spot, the United Arab Emirates presents its share of hurdles, particularly in the areas of applying for a visa, navigating the intricacies of medical insurance, and procuring age-restricted products.

On the other end of the spectrum, standing out as a prime example of efficiency for foreigners, is Germany. It boasts a majority of seamless verification processes during critical steps, including applying for a visa, boarding a flight, checking into a hotel, activating a new mobile phone or SIM card, opening a bank account, and completing medical insurance paperwork.

It also needs to be highlighted that identity verification use cases vary depending on the country, shaped by the specific nuances of local migration laws. For instance, digital nomads in the UAE and US tend to apply for work permits more frequently than their counterparts elsewhere.

Race against time

Just imagine the bureaucratic labyrinth of numerous registrations, verifications, and account openings with essential organizations in a new location that must be navigated by nomads within just a few weeks or a month.

The most prevalent issue associated with the verification process, cited by 19 percent of the survey's respondents, revolves around document validity periods. Some identification documents come with expiration dates, and for a digital nomad who is far from their home country, renewing these documents on time can pose significant challenges.

The challenge of providing proof of residency is cited by another 19 percent of respondents. Digital nomads often lack a fixed residential address, making it hard to furnish traditional proof-of-residency documents like utility bills or rental agreements.

Linked to the previous point, 18 percent of respondents highlighted the challenge of frequently changing locations. Constant travel and shifts in location can result in inconsistencies in the information provided during ID verification, potentially causing delays or rejections. Lastly, trust and credibility are a top concern for another 18 percent of nomads. They may encounter skepticism or a lack of trust from institutions due to the unconventional nature of their lifestyle and work arrangements.

“Verification poses a daunting task for digital nomads as each country and business enforces its unique rules, often lacking streamlined processes for foreign document verification. In the era of global mobility, businesses and nations cannot ignore this new breed of customers and need to carefully review their users’ journeys to elevate the standards of identity verification processes, making them both simple and secure,”—said Henry Patishman, Executive Vice President of Identity Verification Solutions at Regula.

*The research was initiated by Regula and conducted by Sapio Research in September 2023 using an online survey of digital nomads and Fraud Prevention decision makers across the Software/Tech, Financial and Banking Services, Technology, Telecoms, Travel and Hospitality sectors, and others. The respondent geography included the US, UK, Germany, Spain, UAE, and Mexico.

About Regula

With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.

Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.

Learn more at regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116009610/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye